Literature DB >> 27566609

The primary patency of drug-eluting balloon versus conventional balloon angioplasty in hemodialysis patients with arteriovenous fistula stenoses.

Mehmet Burak Çildağ1, Ömer Faruk Kutsi Köseoğlu2, Hakan Akdam3, Yavuz Yeniçerioğlu3.   

Abstract

OBJECTIVE: The aim of this article is to assess and compare the rate of primary patency achieved by drug-eluting balloon angioplasty (DEBA) and conventional balloon angioplasty (CBA) in hemodialysis arteriovenous fistula stenoses.
METHODS: This retrospective study consists of 52 patients with significant arteriovenous fistulas stenoses who were treated with DEBA (n = 26) or CBA (n = 26) between January 2013 and January 2015. Only those patients with postprocedural technical and clinical success of 100 % were selected from the database. Primary patency rates of fistulas at 6 and 12 months were evaluated with Doppler ultrasonography as well as clinically. The Kaplan-Meier method was used to compare the primary assisted patency rates for the two groups.
RESULTS: The type of AVFs were 41 (78.8 %) radiocephalic and 11 (21.2 %) brachiocephalic. Primary patency rates between the DEBA and CBA group had a statistically significant difference at 12 months (p < 0.05). However there was no statistically significant difference at the 6-month follow-up period (p = 0.449). There was no statistically significant difference among the patient age, patient gender and fistula type of the two groups (p > 0.05).
CONCLUSION: Drug-eluting balloon angioplasty proved to be an effective treatment of hemodialysis AVFs stenosis, with a high primary patency rate at 12 months.

Entities:  

Keywords:  Arteriovenous fistula; Conventional balloon angioplasty; Drug-eluting balloon angioplasty; Primary patency; Stenosis; Survival time

Mesh:

Substances:

Year:  2016        PMID: 27566609     DOI: 10.1007/s11604-016-0577-8

Source DB:  PubMed          Journal:  Jpn J Radiol        ISSN: 1867-1071            Impact factor:   2.374


  19 in total

Review 1.  Stenosis in hemodialysis arteriovenous fistula: evaluation and treatment.

Authors:  Rodrigo P Campos; Marcelo M Do Nascimento; Domingos C Chula; Daniel E Do Nascimento; Miguel C Riella
Journal:  Hemodial Int       Date:  2006-04       Impact factor: 1.812

2.  Long-term follow-up after treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter.

Authors:  Bruno Scheller; Yvonne P Clever; Bettina Kelsch; Christoph Hehrlein; Wolfgang Bocksch; Wolfgang Rutsch; Dariush Haghi; Ulrich Dietz; Ulrich Speck; Michael Böhm; Bodo Cremers
Journal:  JACC Cardiovasc Interv       Date:  2012-03       Impact factor: 11.195

3.  KDOQI clinical practice guidelines and clinical practice recommendations--2006 updates.

Authors:  JoAnne Gilmore
Journal:  Nephrol Nurs J       Date:  2006 Sep-Oct       Impact factor: 0.959

4.  Percutaneous maintenance and salvage of dysfunctional arteriovenous fistulae and grafts by nephrologists in Australia.

Authors:  Murty Mantha; John P Killen; Richard Baer; Janice Moffat
Journal:  Nephrology (Carlton)       Date:  2011-01       Impact factor: 2.506

5.  Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery.

Authors:  D I Axel; W Kunert; C Göggelmann; M Oberhoff; C Herdeg; A Küttner; D H Wild; B R Brehm; R Riessen; G Köveker; K R Karsch
Journal:  Circulation       Date:  1997-07-15       Impact factor: 29.690

6.  Venous neointimal hyperplasia in polytetrafluoroethylene dialysis grafts.

Authors:  P Roy-Chaudhury; B S Kelly; M A Miller; A Reaves; J Armstrong; N Nanayakkara; S C Heffelfinger
Journal:  Kidney Int       Date:  2001-06       Impact factor: 10.612

7.  Paclitaxel-coated versus plain balloon angioplasty for dysfunctional arteriovenous fistulae: one-year results of a prospective randomized controlled trial.

Authors:  Panagiotis M Kitrou; Stavros Spiliopoulos; Konstantinos Katsanos; Evangelos Papachristou; Dimitris Siablis; Dimitris Karnabatidis
Journal:  J Vasc Interv Radiol       Date:  2014-12-24       Impact factor: 3.464

8.  Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents.

Authors:  Gregg W Stone; Jeffrey W Moses; Stephen G Ellis; Joachim Schofer; Keith D Dawkins; Marie-Claude Morice; Antonio Colombo; Erick Schampaert; Eberhard Grube; Ajay J Kirtane; Donald E Cutlip; Martin Fahy; Stuart J Pocock; Roxana Mehran; Martin B Leon
Journal:  N Engl J Med       Date:  2007-02-12       Impact factor: 91.245

9.  Paclitaxel balloon coating, a novel method for prevention and therapy of restenosis.

Authors:  Bruno Scheller; Ulrich Speck; Claudia Abramjuk; Ulrich Bernhardt; Michael Böhm; Georg Nickenig
Journal:  Circulation       Date:  2004-08-09       Impact factor: 29.690

10.  Mechanisms of angioplasty in hemodialysis fistula stenoses evaluated by intravascular ultrasound.

Authors:  C J Davidson; G E Newman; K H Sheikh; K Kisslo; R S Stack; S J Schwab
Journal:  Kidney Int       Date:  1991-07       Impact factor: 10.612

View more
  4 in total

1.  Paclitaxel-Coated Balloon versus Plain Balloon Angioplasty for Dysfunctional Autogenous Radiocephalic Arteriovenous Fistulas: A Prospective Randomized Controlled Trial.

Authors:  Jong Woo Kim; Jeong Ho Kim; Sung Su Byun; Jin Mo Kang; Ji Hoon Shin
Journal:  Korean J Radiol       Date:  2020-07-27       Impact factor: 3.500

2.  Use of Paclitaxel Eluting Stents in Arteriovenous Fistulas: A Pilot Study.

Authors:  Krystal Dinh; Shannon D Thomas; Tae Cho; John Swinnen; Phillip Crowe; Ramon L Varcoe
Journal:  Vasc Specialist Int       Date:  2019-12-31

3.  Drug-eluting balloon (DEB) versus plain old balloon angioplasty (POBA) in the treatment of failing dialysis access: A prospective randomized trial.

Authors:  Torbjörn Fransson; Anders Gottsäter; Mohammad Abdulrasak; Martin Malina; Timothy Resch
Journal:  J Int Med Res       Date:  2022-03       Impact factor: 1.671

4.  Drug-coated balloon versus conventional balloon angioplasty of hemodialysis arteriovenous fistula or graft: A systematic review and meta-analysis of randomized controlled trials.

Authors:  Min-Tsun Liao; Meng-Kan Chen; Mu-Yang Hsieh; Nai-Lun Yeh; Kuo-Liong Chien; Chih-Ching Lin; Chih-Cheng Wu; Wei-Chu Chie
Journal:  PLoS One       Date:  2020-04-14       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.